FDA Drug Approvals Q1 2026
Hematology/Oncology Lifyorli (relacorilant) Relacorilant is a glucocorticoid receptor (GR) antagonist indicated for treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with nab- …